Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00283127
Other study ID # 2.2005.1223
Secondary ID
Status Completed
Phase N/A
First received January 26, 2006
Last updated March 2, 2010
Start date February 2006
Est. completion date September 2006

Study information

Verified date January 2009
Source Norwegian Institute of Public Health
Contact n/a
Is FDA regulated No
Health authority Norway: The Data InspectorateNorway: Directorate of Health
Study type Interventional

Clinical Trial Summary

Urogenital Chlamydia trachomatis infection is the most common bacterial sexually transmitted infection in Norway. Urogential C.trachomatis infection can easily be treated with antibiotics. However, left untreated it is a major cause of pelvic inflammatory disease (PID) that can lead to complications such as infertility, ectopic pregnancy and chronic pelvic pain in women. Most infections are asymptomatic and many do not seek the doctor for testing. Therefore cases remain undetected and untreated.We want to determine the efficacy and feasibility of screening for urogenital C. trachomatis infection with home sampling (intervention) compared to the current strategy of conventional sampling at the doctor's office (control) in identifying men and women aged 18-25 years with urogenital C.trachomatis infection (Part A). We also want to identify factors influencing the acceptability of home sampling for C.trachomatis infections (Part B)and determine factors associated with C.trachomatis infections (Part C).


Description:

Study design The different objectives will be addressed through a complex design with several sub-studies.

Part A is a randomised control trial where we compare the intervention group who will be offered home-sampling and recieve a package by mail (containing information on urogenital C.trachomatis infections, sampling eqiupment for urine tests and a questionnaire) with a control group who will continue with todays system of conventional sampling at the doctores office (no intervention). The study population are all men and women between 18-25 years of age in Rogaland County in Norway. The population register will be used to randomly assigne to either the intervention group or the control group.The intervention group will be asked to take a urine sample and send this by mail to the laboratory for analysis within three months after the invitation, and to fill out and return a questionnaire. For the ones in the control group all samples(urethral or cervical swabs or urine samples)taken within the same three months will be sendt to the same laboratory. In this part of the study we will measure the yield ratio for the tested, diagnosed and treated in the two groupsafter the study period of three months. All samples either obtained at home or at the physician's office, will be analyzed by BDProbeTec ET Chlamydia Amplified DNA assay. This is a well documented Nucleid Acid amplification method. Samples will be analysed according to manufactures instructions. Data on number of tested and diagnosed in the two groups will be collected from Stvanger University Hospital. Data on number of treated will be collected from the Norwegain Prescription Database by merging the study dataset with their datafiles. This way we will recive information on who has received treatment for C.rachomatis within one month after after a positive C.trachomatis test.

In Part B a case-cohort from the intervention group (Part A) consisting of a random selection of respondents and non-respondents will be used to determine the feasibility of home sampling as a screening strategy by measuring the risk (OR) related to different factors that determined response. Data are collected through selfadminitered questionnaires.

Part C is a cross sectional study consisting of all respondents in the intervention group. In this part we will measure Prevalence Ratio(PR) of urogential C.trachomatis infections associated with different factors by comparing C.trachomatis positive and C.trachomatis negative in the intervention group.

Part D is an economic study which will be addressed in a separate protocol.


Recruitment information / eligibility

Status Completed
Enrollment 41719
Est. completion date September 2006
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- All persons in the population register in Rogaland County from 18-25 years of age (born between 1/1-1980 - 31/12 -1987) registered 01.11.05. Per 11.11.2005 the size of this population was 41 793. The age cut off is decided because this is the age group with the highest incidence of Chlamydia infections.

Exclusion Criteria:

- All persons in the population register in Rogaland born between 1/1-1980 - 31/12 -1987 registered as:

- living abroad (including Svalbard) - 6 persons

- without (permanent) address - 49 persons

- with client address- 6 persons with secret adress - 16 persons

- military - 1 person

In total 78 persons were excluded

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Procedure:
Home sampling (urine test) for uro-genital C.trachomatis.


Locations

Country Name City State
Norway Norwegain Institute of Public Health Oslo

Sponsors (1)

Lead Sponsor Collaborator
Norwegian Institute of Public Health

Country where clinical trial is conducted

Norway, 

References & Publications (6)

Andersen B, Olesen F, Møller JK, Østergaard L. Population-based strategies for outreach screening of urogenital Chlamydia trachomatis infections: a randomized, controlled trial. J Infect Dis. 2002 Jan 15;185(2):252-8. Epub 2002 Jan 3. — View Citation

Bakken IJ, Skjeldestad FE, Nordbø SA. [Chlamydia trachomatis infection in women seeking termination of pregnancy 1985-2000]. Tidsskr Nor Laegeforen. 2004 Jun 17;124(12):1638-40. Norwegian. — View Citation

Schachter J. Chlamydial infections. West J Med. 1990 Nov;153(5):523-34. Review. — View Citation

Strand RH, Skjeldestad FE, Øvreness T, Nordbø SA. [Chlamydia trachomatis--pattern of testing and prevalence among young women]. Tidsskr Nor Laegeforen. 2004 Jun 17;124(12):1636-7. Norwegian. — View Citation

van Bergen J, Götz HM, Richardus JH, Hoebe CJ, Broer J, Coenen AJ; PILOT CT study group. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. Sex Transm Infect. 2005 Feb;81(1):17-23. — View Citation

Van Der Pol B, Ferrero DV, Buck-Barrington L, Hook E 3rd, Lenderman C, Quinn T, Gaydos CA, Lovchik J, Schachter J, Moncada J, Hall G, Tuohy MJ, Jones RB. Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol. 2001 Mar;39(3):1008-16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Yield ratio tested for uro-genital C.trachomatis infection
Primary Yield ratio diagnosed for uro-genital C.trachomatis infection
Primary Yield ratio treated for uro-genital C.trachomatis infection
See also
  Status Clinical Trial Phase
Completed NCT03676816 - Self Sampling for Rapid Turnaround Testing in the Emergency Department N/A
Completed NCT00213018 - Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Phase 2
Completed NCT00827970 - Randomized Population-Based Study on Chlamydia Trachomatis Screening N/A
Withdrawn NCT01358799 - Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System N/A
Completed NCT01733069 - Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System N/A
Completed NCT00978848 - Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing N/A
Completed NCT02391233 - Multimedia WORTH With Black Drug-Involved Women on Probation N/A
Completed NCT00973466 - Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients N/A
Completed NCT03071510 - Evaluation of the Atlas Genetics io® CTNG System
Recruiting NCT04446611 - Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes N/A
Completed NCT01329588 - Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers Phase 4
Not yet recruiting NCT06216964 - Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study N/A
Terminated NCT02795975 - Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples N/A
Completed NCT00213057 - Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand Phase 1
Completed NCT00207454 - Optimizing Strategies to Improve STD Partner Services Phase 1
Completed NCT00177437 - Home Screening for Chlamydia Surveillance Phase 3
Completed NCT02787109 - Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years Phase 1
Completed NCT01665690 - Washington State Community Expedited Partner Treatment (EPT) Trial Phase 4
Completed NCT02128620 - A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour N/A
Completed NCT00618449 - Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Phase 4